Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Data Links microRNA-150 to Atrial Fibrillation in Heart Failure Patients

Premium

Rosetta Genomics this week announced the publication of data by company researchers showing that downregulation of microRNA-150 is correlated to atrial fibrillation (AF) in patients with chronic systolic heart failure.

The report, which appeared the American Journal of Cardiology, demonstrated that the miRNA's expression was 3.2-fold lower in the platelets and serum of heart failure patients with AF compared with those patients without the arrhythmia.

The serum levels of miR-150 were correlated to platelet levels of miR-150 in patients with AF, Rosetta stated.

Meanwhile, a comparison of miRNA expression levels in platelets from patients with heart failure and controls, none of the miRNAs examined in the study showed significant differences between the groups — a finding the company said shows that platelet miRNA expression levels are not significantly altered by heart failure.

Rosetta is currently developing an assay that uses blood-based miRNAs as biomarker for the early diagnosis and risk stratification of heart failure patients. The test is expected to be available in 2017.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.